Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 168682, 14 pages
http://dx.doi.org/10.1155/2015/168682
Research Article

Bladder Carcinoma Data with Clinical Risk Factors and Molecular Markers: A Cluster Analysis

1Urology Department, Hospital Clinico San Carlos, Complutense University, Instituto de Investigacion Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain
2Natural Computing Laboratory (LCoN), Mackenzie Presbyterian University, 01302-000 São Paulo, SP, Brazil
3Clinical Analysis Department, Hospital Clinico Universitario San Carlos, 28040 Madrid, Spain
4Odontology School, Complutense University, 28040 Madrid, Spain
5Biomedical Research Institute of Salamanca/BISITE Research Group, University of Salamanca, Edificio I+D+i, 37008 Salamanca, Spain

Received 28 September 2014; Revised 5 January 2015; Accepted 15 January 2015

Academic Editor: Isabelle Bichindaritz

Copyright © 2015 Enrique Redondo-Gonzalez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Colombel, M. Soloway, H. Akaza et al., “Epidemiology, staging, grading, and risk stratification of bladder cancer,” European Urology, Supplements, vol. 7, no. 10, pp. 618–626, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Brausi, J. A. Witjes, D. Lamm et al., “A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group,” The Journal of Urology, vol. 186, no. 6, pp. 2158–2167, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Burger, J. W. F. Catto, G. Dalbagni et al., “Epidemiology and risk factors of urothelial bladder cancer,” European Urology, vol. 63, no. 2, pp. 234–241, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. S. L. Parker, T. Tong, S. Bolden, and P. A. Wingo, “Cancer statistics, 1996,” CA: A Cancer Journal for Clinicians, vol. 46, no. 1, pp. 5–27, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. J. P. Stein, G. D. Grossfeld, D. A. Ginsberg et al., “Prognostic markers in bladder cancer: a contemporary review of the literature,” Journal of Urology, vol. 160, no. 3, pp. 645–659, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. H. W. Herr, “Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome,” The Journal of Urology, vol. 163, no. 1, pp. 60–62, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. M. F. Botteman, C. L. Pashos, A. Redaelli, B. Laskin, and R. Hauser, “The health economics of bladder cancer: a comprehensive review of the published literature,” PharmacoEconomics, vol. 21, no. 18, pp. 1315–1330, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. R. J. Sylvester, A. P. van der Meijden, W. Oosterlinck et al., “Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials,” European Urology, vol. 49, no. 3, pp. 466–477, 2006. View at Publisher · View at Google Scholar
  9. J. Moreno Sierra, M. L. Maestro de Las Casas, E. Redondo González et al., “Epidermal growth factor receptor (EGFR) in the prognosis of bladder carcinoma. Experience of 5 years,” Archivos Espanoles de Urologia, vol. 53, no. 4, pp. 323–331, 2000. View at Google Scholar
  10. J. M. Sierra, M. L. M. de las Casas, M. D. O. Heredia et al., “Nuevo método cuantitativo para determinar la proteina P53 en carcinomas vesicales,” Archivos Espanoles de Urologia, vol. 50, no. 4, pp. 347–353, 1997. View at Google Scholar · View at Scopus
  11. J. Moreno Sierra, M. L. Maestro de las Casas, E. Redondo Gonzalez et al., “P185 (Neu) oncoprotein in the prognosis of bladder carcinoma. Experience of 5 years,” Archivos Españoles de Urología, vol. 53, pp. 238–244, 2000. View at Google Scholar
  12. J. Moreno Sierra, M. L. M. de las Casas, C. F. Pérez et al., “Quantification of p53 oncoprotein in bladder carcinoma: 5-year experience,” Archivos Espanoles de Urologia, vol. 52, no. 3, pp. 220–227, 1999. View at Google Scholar · View at Scopus
  13. J. M. Sierra, M. M. de las Casas, M. D. O. Heredia, J. H. Gutiérrez, and L. R. Estevez, “Quantitative determination of epidermal growth factor urothelial receptor (EGFR) in superficial and invasive bladder carcinoma,” Actas Urologicas Espanolas, vol. 18, no. 3, pp. 215–220, 1994. View at Google Scholar · View at Scopus
  14. M. A. Brausi, “Primary prevention and early detection of bladder cancer: two main goals for urologists,” European Urology, vol. 63, no. 2, pp. 242–243, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Ferlay, H. Shin, F. Bray, D. Forman, C. Mathers, and D. Parkin, GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10, International Agency for Research on Cancer, Lyon, France, 2010.
  16. C. Bosetti, P. Bertuccio, L. Chatenoud, E. Negri, C. la Vecchia, and F. Levi, “Trends in mortality from urologic cancers in Europe, 1970–2008,” European Urology, vol. 60, no. 1, pp. 1–15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Ferlay, G. Randi, C. Bosetti et al., “Declining mortality from bladder cancer in Europe,” BJU International, vol. 101, no. 1, pp. 11–19, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. N. D. Freedman, D. T. Silverman, A. R. Hollenbeck, A. Schatzkin, and C. C. Abnet, “Association between smoking and risk of bladder cancer among men and women,” Journal of the American Medical Association, vol. 306, no. 7, pp. 737–745, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. Z. Kirkali, T. Chan, M. Manoharan et al., “Bladder cancer: epidemiology, staging and grading, and diagnosis,” Urology, vol. 66, no. 6, pp. 4–34, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. D. T. Silverman, S. S. Devesa, L. E. Moore, and N. Rothman, “Bladder cancer,” in Cancer Epidemiology and Prevention, D. Schottenfeld and J. F. Fraumeni, Eds., pp. 1101–1128, Oxford University Press, New York, NY, USA, 3rd edition, 2006. View at Google Scholar
  21. C. M. Samanic, M. Kogevinas, D. T. Silverman et al., “Occupation and bladder cancer in a hospital-based case-control study in Spain,” Occupational and Environmental Medicine, vol. 65, no. 5, pp. 347–353, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Rushton, S. Bagga, R. Bevan et al., “Occupation and cancer in Britain,” British Journal of Cancer, vol. 102, no. 9, pp. 1428–1437, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Koutros, D. T. Silverman, D. Baris et al., “Hair dye use and risk of bladder cancer in the New England bladder cancer study,” International Journal of Cancer, vol. 129, no. 12, pp. 2894–2904, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. M. M. Ros, M. Gago-Dominguez, K. K. H. Aben et al., “Personal hair dye use and the risk of bladder cancer: a case–control study from The Netherlands,” Cancer Causes & Control, vol. 23, no. 7, pp. 1139–1148, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Rafnar, S. H. Vermeulen, P. Sulem et al., “European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene,” Human Molecular Genetics, vol. 20, no. 21, pp. 4268–4281, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. M. K. B. Parmar, L. S. Freedman, T. B. Hargreave, and D. A. Tolley, “Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council subgroup on superficial bladder cancer (urological cancer working party),” Journal of Urology, vol. 142, no. 2, pp. 284–288, 1989. View at Google Scholar · View at Scopus
  27. T. Shinka, A. Hirano, Y. Uekado, and T. Ohkawa, “Clinical study of prognostic factors of superficial bladder cancer treated with intravesical Bacillus Calmette-Guerin,” British Journal of Urology, vol. 66, no. 1, pp. 35–39, 1990. View at Publisher · View at Google Scholar · View at Scopus
  28. L. A. L. M. Kiemeney, J. A. Witjes, R. P. Heijbroek, F. M. J. Debruyne, and A. L. M. Verbeek, “Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer,” European Journal of Cancer Part A: General Topics, vol. 30, no. 11, pp. 1621–1625, 1994. View at Google Scholar · View at Scopus
  29. K. H. Kurth, L. Denis, R. Sylvester, F. M. J. Debruyne, M. Pavone-Macaluso, and W. Oosterlinck, “Factors affecting recurrence and progression in superficial bladder tumours,” European Journal of Cancer Part A: General Topics, vol. 31, no. 11, pp. 1840–1846, 1995. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Millán-Rodríguez, G. Chéchile-Toniolo, J. Salvador-Bayarri, J. Palou, and J. Vicente-Rodríguez, “Multivariate analysis of the prognostic factors of primary superficial bladder cancer,” Journal of Urology, vol. 163, no. 1, pp. 73–78, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. M. S. Soloway, M. Sofer, and A. Vaidya, “Contemporary management of stage T1 transitional cell carcinoma of the bladder,” Journal of Urology, vol. 167, no. 4, pp. 1573–1583, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Miyamoto, J. S. Miller, D. A. Fajardo, T. K. Lee, G. J. Netto, and J. I. Epstein, “Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system,” Pathology International, vol. 60, no. 1, pp. 1–8, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Miyamoto, F. Brimo, L. Schultz et al., “Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post-world Health Organization/International Society of Urological Pathology classification cohort from a single academic center,” Archives of Pathology and Laboratory Medicine, vol. 134, no. 8, pp. 1160–1163, 2010. View at Google Scholar · View at Scopus
  34. X.-R. Wu, “Urothelial tumorigenesis: a tale of divergent pathways,” Nature Reviews Cancer, vol. 5, no. 9, pp. 713–725, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. A. P. Mitra, R. H. Datar, and R. J. Cote, “Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification,” Journal of Clinical Oncology, vol. 24, no. 35, pp. 5552–5564, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Fradet, “Prognostic factors. Back to the future,” in Superficial Bladder Cancer, W. R. Fair and F. Pagano, Eds., pp. 57–70, CRC Press, New York, NY, USA, 1997. View at Google Scholar
  37. P. Rischmann, H. Bittard, D. Chopin et al., “AFU recommendations 1998. ‘Committee on Cancer of the French Association of Urology’,” Progres en Urologie, vol. 12, no. 5, pp. 1159–1160, 2002. View at Google Scholar · View at Scopus
  38. F. Millán-Rodríguez, G. Chéchile-Toniolo, J. Salvador-Bayarri, J. Palou, F. Algaba, and J. Vicente-Rodríguez, “Primary superficial bladder cancer risk groups according to progression, mortality and recurrence,” The Journal of Urology, vol. 164, no. 3, pp. 680–684, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. B. W. G. van Rhijn, T. C. M. Zuiverloon, A. N. Vis et al., “Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer,” European Urology, vol. 58, no. 3, pp. 433–441, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Fernandez-Gomez, R. Madero, E. Solsona et al., “The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables,” European Urology, vol. 60, no. 3, pp. 423–430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. P. R. Srinivas, S. Srivastava, S. Hanash, and J. Wright G.L., “Proteomics in early detection of cancer,” Clinical Chemistry, vol. 47, no. 10, pp. 1901–1911, 2001. View at Google Scholar · View at Scopus
  42. G. J. Netto, “Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?” Nature Reviews Urology, vol. 9, no. 1, pp. 41–51, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Røtterud, J. M. Nesland, A. Berner, and S. D. Fosså, “Expression of the epidermal growth factor receptor family in normal and malignant urothelium,” BJU International, vol. 95, no. 9, pp. 1344–1350, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Simonetti, R. Russo, G. Ciancia, V. Altieri, G. de Rosa, and L. Insabato, “Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and FISH analysis of c-erbB-2 gene and chromosome 17,” International Journal of Surgical Pathology, vol. 17, no. 3, pp. 198–205, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. D. E. Neal, R. R. Hall, C. Marsh, P. D. Abel, J. R. C. Sainsbury, and A. L. Harris, “Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours,” The Lancet, vol. 1, no. 8425, pp. 366–368, 1985. View at Publisher · View at Google Scholar · View at Scopus
  46. D. E. Neal, L. Sharples, K. Smith, J. Fennelly, R. R. Hall, and A. L. Harris, “The epidermal growth factor receptor and the prognosis of bladder cancer,” Cancer, vol. 65, no. 7, pp. 1619–1625, 1990. View at Google Scholar · View at Scopus
  47. A. J. Colquhoun and J. K. Mellon, “Epidermal growth factor receptor and bladder cancer,” Postgraduate Medical Journal, vol. 78, no. 924, pp. 584–589, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Mellon, C. Wright, P. Kelly, C. H. Horne, and D. E. Neal, “Long-term outcome related to epidermal growth factor receptor status in bladder cancer,” The Journal of Urology, vol. 153, pp. 919–925, 1995. View at Google Scholar
  49. J. E. Nutt, J. K. Mellon, K. Qureshi, and J. Lunec, “Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours,” British Journal of Cancer, vol. 78, no. 2, pp. 215–220, 1998. View at Publisher · View at Google Scholar · View at Scopus
  50. B. D. Kavanagh, P.-S. Lin, P. Chen, and R. K. Schmidt-Ullrich, “Radiation-induced enhanced proliferation of human squamous cancer cells in vitro: a release from inhibition by epidermal growth factor,” Clinical Cancer Research, vol. 1, no. 12, pp. 1557–1562, 1995. View at Google Scholar · View at Scopus
  51. H. Roh, J. Pippin, and J. A. Drebin, “Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu,” Cancer Research, vol. 60, no. 3, pp. 560–565, 2000. View at Google Scholar · View at Scopus
  52. R. Gandour-Edwards, P. N. Lara Jr., A. K. Folkins et al., “Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?” Cancer, vol. 95, no. 5, pp. 1009–1015, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. Z. Latif, A. D. Watters, I. Dunn, K. Grigor, M. A. Underwood, and J. M. S. Bartlett, “HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?” European Journal of Cancer, vol. 40, no. 1, pp. 56–63, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Eissa, H. S. Ali, A. H. Al Tonsi, A. Zaglol, and O. El Ahmady, “HER2/neu expression in bladder cancer: relationship to cell cycle kinetics,” Clinical Biochemistry, vol. 38, no. 2, pp. 142–148, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Bolenz, S. F. Shariat, P. I. Karakiewicz et al., “Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder,” BJU International, vol. 106, no. 8, pp. 1216–1222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Krüger, G. Weitsch, H. Büttner et al., “Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome,” International Journal of Oncology, vol. 21, no. 5, pp. 981–987, 2002. View at Google Scholar · View at Scopus
  57. V. Ravery, D. Grignon, J. Angulo et al., “Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression in invasive bladder cancer,” Urological Research, vol. 25, no. 1, pp. 9–17, 1997. View at Publisher · View at Google Scholar · View at Scopus
  58. R. E. Jimenez, M. Hussain, F. J. Bianco Jr. et al., “Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors,” Clinical Cancer Research, vol. 7, no. 8, pp. 2440–2447, 2001. View at Google Scholar · View at Scopus
  59. A. Chakravarti, K. Winter, C.-L. Wu et al., “Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group,” International Journal of Radiation Oncology Biology Physics, vol. 62, no. 2, pp. 309–317, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. C. Bolenz and Y. Lotan, “Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers,” Cancer Biology and Therapy, vol. 10, no. 5, pp. 407–415, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. P. C. H. Chen, H. J. Yu, Y. H. Chang, and C. C. Pan, “Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression,” Journal of Clinical Pathology, vol. 66, no. 2, pp. 113–119, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. T. H. Ecke, H. H. Schlechte, G. Schulze, S. V. Lenk, and S. A. Loening, “Four tumour markers for urinary bladder cancer—tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation,” Anticancer Research, vol. 25, no. 1, pp. 635–641, 2005. View at Google Scholar · View at Scopus
  63. C. A. Finlay, P. W. Hinds, T. H. Tan, D. Eliyahu, M. Oren, and A. J. Levine, “Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life,” Molecular and Cellular Biology, vol. 8, no. 2, pp. 531–539, 1988. View at Google Scholar · View at Scopus
  64. B. George, R. H. Datar, L. Wu et al., “p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer,” Journal of Clinical Oncology, vol. 25, no. 34, pp. 5352–5358, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. Z. Popov, A. Hoznek, M. Colombel et al., “The prognostic value of p53 nuclear overexpression and MIB1 as a proliferative marker in transitional cell carcinoma of the bladder,” Cancer, vol. 80, no. 8, pp. 1472–1481, 1997. View at Google Scholar
  66. A. S. Sarkis, G. Dalbagni, C. Cordon-Cardo et al., “Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression,” Journal of the National Cancer Institute, vol. 85, no. 1, pp. 53–59, 1993. View at Publisher · View at Google Scholar · View at Scopus
  67. A. S. Sarkis, G. Dalbagni, C. Cordon-Cardo et al., “Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder,” Journal of Urology, vol. 152, no. 2, pp. 388–392, 1994. View at Google Scholar · View at Scopus
  68. S. F. Shariat, C. Bolenz, P. I. Karakiewicz et al., “P53 expression in patients with advanced urothelial cancer of the urinary bladder,” BJU International, vol. 105, no. 4, pp. 489–495, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Saidi, Z. Popov, S. Stavridis, V. Janevska, and S. Panov, “Digital quantitative immunofluorescent detection of p53 protein in urinary bladder cancer tissue samples,” Prilozi, vol. 34, pp. 167–175, 2013. View at Google Scholar
  70. F. K. Mostofi, C. J. J. Davis, and I. A. Sesterhenn, Histological Typing of Urinary Bladder Tumours, WHO (World Health Organization) International Histological Classification of Tumours, Springer, Berlin, Germany, 1999.
  71. L. H. Sobin and C. Wittekind, TNM: Classification of Malignant Tumours, Wiley-Liss, 5th edition, 1997.
  72. A. K. Jain, M. N. Murty, and P. J. Flynn, “Data clustering: a review,” ACM Computing Surveys (CSUR), vol. 31, no. 3, pp. 264–323, 1999. View at Publisher · View at Google Scholar · View at Scopus
  73. L. Kaufman and P. J. Rousseeuw, Finding Groups in Data: An Introduction to Cluster Analysis, Wiley-Interscience, New York, NY, USA, 2005.
  74. B. S. Everitt, S. Landau, and M. Leese, Cluster Analysis, John Wiley & Sons, New York, NY, USA, 2009.
  75. D. Pyle, Data Preparation for Data Mining (The Morgan Kaufmann Series in Data Management Systems), Morgan Kaufmann, Boston, Mass, USA, 1999.
  76. S. Zhang, C. Zhang, and Q. Yang, “Data preparation for data mining,” Applied Artificial Intelligence, vol. 17, no. 5-6, pp. 375–381, 2003. View at Publisher · View at Google Scholar · View at Scopus